Veterinary Medicine Information website

Ataxxa 500 mg/100 mg spot-on solution for dogs over 4 kg up to 10 kg

Authorised
  • Permethrin
  • Imidacloprid

Product identification

Medicine name:
Ataxxa 500 mg/100 mg spot-on solution for dogs over 4 kg up to 10 kg
Active substance:
  • Permethrin
  • Imidacloprid
Target species:
  • Dog
Route of administration:
  • Spot-on use

Product details

Active substance and strength:
  • Permethrin
    500.00
    milligram(s)
    /
    1.00
    Pipette
  • Imidacloprid
    100.00
    milligram(s)
    /
    1.00
    Pipette
Pharmaceutical form:
  • Spot-on solution
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP53AC54
Authorisation status:
  • Valid
Authorised in:
  • Germany
Available in:
  • Germany
Package description:
  • White polypropylene pipette closed with a polyethylene cap. Each pipette is packed in apolyethylene terephthalate/aluminium/low density polyethylene triplex bag.3 ml pipette containing 1 ml of solution.Box containing 1 pipette.
  • White polypropylene pipette closed with a polyoxymethylene cap. Each pipette is packed in apolyethylene terephthalate/aluminium/low density polyethylene triplex bag.3 ml pipette containing 1 ml of solution.Box containing 3 pipettes.
  • White polypropylene pipette closed with a polyethylene cap. Each pipette is packed in apolyethylene terephthalate/aluminium/low density polyethylene triplex bag.3 ml pipette containing 1 ml of solution.Box containing 4 pipettes.
  • White polypropylene pipette closed with a polyethylene cap. Each pipette is packed in apolyethylene terephthalate/aluminium/low density polyethylene triplex bag.3 ml pipette containing 1 ml of solution.Box containing 6 pipettes.
  • White polypropylene pipette closed with a polyoxymethylene cap. Each pipette is packed in apolyethylene terephthalate/aluminium/low density polyethylene triplex bag.3 ml pipette containing 1 ml of solution.Box containing 10 pipettes.
  • White polypropylene pipette closed with a polyethylene cap. Each pipette is packed in apolyethylene terephthalate/aluminium/low density polyethylene triplex bag.3 ml pipette containing 1 ml of solution.Box containing 10 pipettes.
  • White polypropylene pipette closed with a polyoxymethylene cap. Each pipette is packed in apolyethylene terephthalate/aluminium/low density polyethylene triplex bag.3 ml pipette containing 1 ml of solution.Box containing 6 pipettes.
  • White polypropylene pipette closed with a polyoxymethylene cap. Each pipette is packed in a polyethylene terephthalate/aluminium/low density polyethylene triplex bag. 3 ml pipette containing 1 ml of solution. Box containing 4 pipettes.
  • White polypropylene pipette closed with a polyoxymethylene cap. Each pipette is packed in apolyethylene terephthalate/aluminium/low density polyethylene triplex bag.3 ml pipette containing 1 ml of solution.Box containing 1 pipette.
  • White polypropylene pipette closed with a polyethylene cap. Each pipette is packed in a polyethylene terephthalate/aluminium/low density polyethylene triplex bag. 3 ml pipette containing 1 ml of solution. Box containing 3 pipettes.

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • KRKA tovarna zdravil d.d. Novo mesto
Marketing authorisation date:
Manufacturing sites for batch release:
  • KRKA tovarna zdravil d.d. Novo mesto
  • TAD Pharma GmbH
Responsible authority:
  • Federal Office Of Consumer Protection And Food Safety
Authorisation number:
  • 402161.00.00
Date of authorisation status change:
Reference member state:
  • Ireland
Procedure number:
  • IE/V/0439/002
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Czechia
  • Estonia
  • France
  • Germany
  • Hungary
  • Italy
  • Latvia
  • Lithuania
  • Netherlands
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • United Kingdom (Northern Ireland)

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
German (PDF)
Published on: 19/12/2024